NEW YORK(GenomeWeb) – Metabolomic Discoveries said today that it has joined the competence consortium NEU2 (new drugs against neurological diseases) to strengthen its product development portfolio in neurodegenerative diseases.

The company will partner with the Fraunhofer Institute for Molecular Biology and Applied Ecology (IME) researcher Ole Pless and researchers at the University Medical Center Hamburg-Eppendorf on a project to identify biomarker candidates for multiple sclerosis in metabolites and regulatory RNA molecules.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.